What is PSA?
Prostate-specific antigen (PSA) is a protein produced by both normal and malignant cells of the prostate gland. It is measured through a simple blood test and serves as a screening marker for prostate health. In clinical practice, PSA is used to detect benign prostatic hyperplasia (BPH), prostatitis (inflammation), and prostate cancer. Normal PSA levels are generally below 4.0 ng/mL, though age-adjusted reference ranges are used by many providers — younger men have lower expected values.
PSA is not specific to cancer. Elevated PSA can result from prostate enlargement (BPH), infection, vigorous exercise, recent ejaculation, or even a long bike ride. This is why PSA is best used as a trend marker over time rather than a single-point diagnostic tool. A slow, steady rise carries different implications than a one-time spike.
How does TRT affect PSA levels?
Testosterone and its more potent metabolite dihydrotestosterone (DHT) stimulate prostate tissue growth and PSA production. When you start TRT, PSA typically rises modestly — averaging 0.3-0.5 ng/mL above baseline over the first 6-12 months — then plateaus. This increase reflects normal androgen-driven prostate stimulation and is expected, not alarming.
A 2014 study published in European Urology followed 1,023 hypogonadal men on testosterone therapy for up to 17 years. The mean PSA increase was 0.44 ng/mL over the entire study period, with the majority of the increase occurring in the first year. After the initial adjustment period, PSA remained stable in most patients. This study is one of the longest-running TRT safety datasets available.
The delivery method can influence PSA response. Injectable testosterone, which produces higher peak levels, may cause slightly more PSA stimulation than transdermal formulations. However, the differences are small and clinically insignificant for most men.
Does TRT cause prostate cancer?
The fear that testosterone causes prostate cancer traces back to the 1940s, when Charles Huggins demonstrated that castration caused prostate cancer regression and that testosterone administration stimulated growth in advanced disease. For decades, this led to the assumption that higher testosterone levels would increase cancer risk. Modern evidence has substantially challenged this narrative.
A 2016 meta-analysis published in The Journal of Urology, analyzing data from over 5,000 men across multiple randomized controlled trials, found no statistically significant increase in prostate cancer incidence among men receiving testosterone therapy compared to placebo. The American Urological Association's 2018 guidelines explicitly state that current evidence does not support an association between TRT and increased prostate cancer risk in men without pre-existing disease.
The TRAVERSE trial, published in 2023 in The New England Journal of Medicine, was the largest randomized controlled trial of testosterone therapy to date (5,246 men, median follow-up of 33 months). While primarily designed to assess cardiovascular outcomes, it also tracked prostate events. The trial found no significant increase in high-grade prostate cancer among testosterone-treated men compared to placebo.
Key takeaway:The old belief that testosterone “feeds” prostate cancer has been largely overturned by modern evidence. Multiple large studies and meta-analyses show no increased prostate cancer risk with physiological-dose TRT. However, monitoring remains essential because prostate cancer is common in aging men regardless of TRT status.
What is the androgen saturation model?
The androgen saturation model, proposed by Dr. Abraham Morgentaler of Harvard Medical School, explains why testosterone does not appear to increase prostate cancer risk at physiological doses. The model posits that androgen receptors in prostate tissue reach saturation at relatively low testosterone levels — approximately 250 ng/dL of serum testosterone. Above this level, additional testosterone does not produce additional prostate stimulation because the receptors are already fully occupied.
This model explains why castrate levels of testosterone (near zero) cause prostate cancer regression — you are below saturation — while restoring testosterone to normal levels through TRT does not stimulate growth further. The prostate responds to the presence or absence of androgens, not to incremental increases above the saturation point.
Multiple clinical studies support the saturation model. Men treated with TRT to high-normal levels (700-1,000 ng/dL) do not show greater prostate growth or PSA increases than those treated to mid-range levels (400-600 ng/dL), consistent with receptor saturation.
How should PSA be monitored on TRT?
PSA monitoring on TRT follows a straightforward protocol. A baseline PSA is drawn before starting therapy — ideally as part of your pre-TRT blood panel. Follow-up PSA checks occur at 3-6 months after starting TRT, then at 12 months, and annually thereafter for men over 40.
The most important metric is not the absolute PSA value — it is the PSA velocity (rate of change over time). A man whose PSA rises from 1.0 to 1.4 ng/mL in the first year of TRT is showing a normal response. A man whose PSA jumps from 1.0 to 2.5 ng/mL in the same timeframe needs evaluation, even though 2.5 ng/mL is technically “normal.”
When should a PSA level trigger concern?
The AUA and Endocrine Society guidelines identify several PSA scenarios that warrant further evaluation — typically referral to a urologist for possible imaging or biopsy.
| Scenario | Threshold | Recommended Action |
|---|---|---|
| Absolute PSA above age-adjusted limit | >4.0 ng/mL (or age-adjusted) | Urological evaluation; consider MRI or biopsy |
| Rapid PSA velocity | >0.75 ng/mL per year | Urological evaluation regardless of absolute level |
| PSA rise above baseline on TRT | >1.0 ng/mL above pre-TRT value | Repeat PSA in 4-6 weeks; if persistent, refer |
| Abnormal digital rectal exam (DRE) | Any nodule or asymmetry | Urological evaluation regardless of PSA |
Context matters for every PSA reading. Did you exercise vigorously or have sex within 48 hours of the draw? (Both can transiently elevate PSA.) Were you taking a 5-alpha reductase inhibitor like finasteride, which artificially lowers PSA by approximately 50%? Is there a history of prostatitis? Always provide your full context to the provider interpreting your results.
Important: If you are taking finasteride or dutasteride (5-alpha reductase inhibitors used for hair loss or BPH), your PSA value should be doubled when interpreting results. These medications suppress PSA production by approximately 50%, which can mask a clinically significant rise. Inform your provider about any 5-ARI use.
Can you take TRT after prostate cancer?
Prostate cancer was historically considered an absolute contraindication to TRT. That position has evolved significantly, though it remains nuanced. The current landscape, as reflected in the AUA's updated guidelines, allows for TRT consideration in carefully selected men who have been treated for prostate cancer and are in remission.
The strongest candidate profile: men who underwent radical prostatectomy for localized disease, have an undetectable PSA (<0.01 ng/mL) for at least one year post-surgery, had favorable pathology (Gleason 6-7, organ-confined), and are experiencing significant quality-of-life impairment from hypogonadism. Several case series have followed such men on TRT for 3-5+ years without increased recurrence rates.
Men treated with radiation therapy (external beam or brachytherapy) are also considered candidates by some specialists, though with more caution since residual prostate tissue remains and biochemical recurrence monitoring is more complex.
This decision requires close collaboration between a TRT provider and the patient's urologist or oncologist. It is not a decision any single provider should make alone, and monitoring must be more intensive than standard TRT protocols.
How do DHT and 5-alpha reductase relate to prostate health?
Dihydrotestosterone (DHT) is converted from testosterone by the 5-alpha reductase enzyme within prostate tissue. DHT is approximately 3-5 times more potent at the androgen receptor than testosterone and is the primary androgen driving prostate growth. This is why 5-alpha reductase inhibitors (finasteride, dutasteride) effectively shrink the prostate and reduce PSA.
TRT raises DHT proportionally to testosterone increases, which contributes to the modest PSA elevation seen in the first year. Men who are sensitive to DHT-driven effects (prostate enlargement symptoms, hair loss) may discuss 5-alpha reductase inhibitor co-therapy with their provider, though this adds medication complexity and its own set of potential side effects.
What are the practical guidelines for PSA on TRT?
For men starting TRT, the practical approach is straightforward. Get a baseline PSA before starting. Recheck at 3-6 months and 12 months. Then check annually for the duration of therapy. Track your values in a spreadsheet or log so trends are visible at a glance.
A modest PSA rise in the first year is expected and normal. A rapid rise, an absolute level above 4.0 ng/mL, or a rise greater than 1.0 ng/mL above your baseline all warrant urological follow-up. A normal PSA does not mean prostate cancer is impossible — it is a screening tool, not a definitive test.
For the full monitoring schedule including all markers beyond PSA, return to our complete TRT blood work guide. For details on every marker in the pre-treatment workup, see the pre-TRT blood panel guide.
Frequently Asked Questions
Does TRT increase prostate cancer risk?
Current evidence does not support the claim that TRT increases prostate cancer risk in men without pre-existing disease. A 2016 meta-analysis in The Journal of Urology analyzing over 5,000 men found no statistically significant increase in prostate cancer among TRT patients. The AUA's 2018 guidelines state that TRT does not appear to increase prostate cancer risk.
How much does PSA increase on TRT?
TRT typically raises PSA by 0.3-0.5 ng/mL within the first 6-12 months, then stabilizes. This modest increase reflects testosterone's stimulatory effect on prostate tissue and is considered a normal response — not a warning sign. A PSA rise greater than 1.0 ng/mL above baseline warrants further evaluation.
Should I check PSA before starting TRT?
Yes. A baseline PSA is recommended for all men over 40 before starting TRT, and many providers check it in younger men with a family history of prostate cancer. The baseline value is essential for tracking PSA velocity (rate of change) during therapy, which is more clinically meaningful than any single PSA number.
Can I take TRT if I had prostate cancer?
Historically, prostate cancer was an absolute contraindication to TRT. That position has evolved. Some urologists and oncologists now consider TRT for select patients in remission, particularly after radical prostatectomy with undetectable PSA. This decision requires close collaboration between your TRT provider and urologist/oncologist.
What PSA level is too high for TRT?
There is no single PSA cutoff that automatically disqualifies TRT. A PSA above 4.0 ng/mL warrants urological evaluation before starting or continuing therapy. More concerning than an absolute number is PSA velocity — a rise of more than 0.75 ng/mL per year, or a rise greater than 1.0 ng/mL above your pre-TRT baseline.